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Lung cancer is histologically divided into two major groups. Small cell 
lung carcinomas (SCLCs) showing rapid growth and early metastases 
comprises approximately 20% of the total incidence. Non-small cell 
lung carcinoma (NSCLC), which includes mainly adenocarcinoma, 
squamous cell carcinoma (SCC) and large cell carcinoma, accounts for 
80%. Surgical resection is the only treatment modality with a reason-
able chance of offering cure, though chemotherapy is widely reserved 
for patients with advanced stages of lung cancer. The WHO classiﬁca-
tion actually deﬁnes nine subgroups of malignant epithelial lung tu-
mours that are either deﬁned by a speciﬁc line of differentiation or the 
presence of mixed phenotypes thus reﬂecting the fact that lung cancer 
is frequently heterogeneous (Travis et al. 2004). 
Histomorphology is and will probably remain the basis for lung cancer 
classiﬁcation. However, this view is been challenged by us and others 
using molecular screening methods that were able to identify lung 
cancer subgroups with distinct survival (see Travis et al. 2004). Before 
we could show by Comparative Genomic Hybridization (CGH) that 
lung cancers carry distinct patterns of chromosomal imbalances being 
associated with tumor differentiation and progression to metastasis (see 
Travis et al. 2004) Thus, the genetic analysis strongly suggests that the 
aggressive biological phenotype of lung cancer is caused by a complex 
and instable genotype which confers the tumor cells with a high prob-
ability to acquire chromosomal imbalances and epigenetic signatures 
necessary for tumour progression and dissemination. Realizing that that 
the existing schemes do not fully characterize lung cancer we recently 
concentrated on the two major parameters used in tumor classiﬁcation, 
i.e. cell size and differentiation. 
Core classiﬁcation of lung cancer.
Speciﬁcations of cell size have entered the denominations of many 
tumor entities and are particularly important for lung cancer. They carry, 
however, several insufﬁciencies. The criteria for deﬁning large cell lung 
carcinoma, for instance, are far less precise than for small cell lung 
cancer. As major inaccuracy, all these descriptions do not differentiate 
between cell size and nuclear size which can differ considerably. Given 
the fact that the tumor behaviour is essentially governed by its genotype 
we felt that there is a need to focus on the nuclear parameters of the 
tumor cell and therefore established the core classiﬁcation. It repre-
sents a categorization of a tumor according to the sizes of its nuclei. In 
addition, the chromosome division ﬁgures are scored by their sizes and 
the presence or absence of tripolar and tetrapolar mitoses. The morpho-
logical assessments correlated signiﬁcantly with the DNA cytometry 
parameters, e.g. small cell lung carcinomas showed the smallest values 
for nuclear size and DNA content being highly signiﬁcantly differ-
ent from adenocarcinomas, large cell lung carcinoma and squamous 
cell carcinoma. Furthermore, the variability of sizes of the nuclei and 
mitoses were signiﬁcantly associated with DNA parameters indicative 
for chromosomal variability (e.g. 2c deviation index, 5c exceeding rate) 
which all represented predictors of poor survival in non-small cell lung 
carcinoma patients. The core classiﬁcation provides insight into the size 
and variability of the chromosome complement and carried prognostic 
signiﬁcance. As a supplement to conventional tumor diagnosis it may 
thus help to better stratify cancer subtypes (Petersen et al., manuscript in 
preparation).
Lung cancer differentiation and tumor suppression.
Lung cancer has been described as a disorder of cellular differentiation, 
in addition to being a disorder of the balance between proliferation and 
cell death. In principle, (terminal) differentiation is associated with a 
stop in cell proliferation. Thus, differentiation-associated genes are 
potential tumor suppressors. We could recently show that this concept 
is true for lung cancer by identifying such genes and by demonstrat-
ing that they indeed carry tumor suppressor function. Furthermore, we 
established a cell model by inducing differentiation in small cell lung 
cancer cell line via treatment with a chemical agent. It was used to 
identify and characterize differentiation-associated genes. 
Identiﬁcation of lung cancer differentiation-associated genes.
The treatment of the SCLC cell line H526 by the differentiation induc-
ing agent 5-bromodeoxyuridine (BrdU) led to a dramatic conver-
sion from suspension cells to adherent cells exhibiting an epithelioid 
phenotype, which remarkably reduced the ability of colony formation 
in soft agar and suppressed the tumor growth rate in nude mice. The 
phenotypic transition was associated with upregulation of SFTPC, 
Nkx2.1, Cx26, IGFBP-rP1, as well as homeobox genes LAGY/HOP, 
PITX1 and HOXB2. It is interesting to note that most of them had been 
identiﬁed in our SSH libraries enriched for genes down-regulated in 
lung cancer cells when we previously compared the gene expression 
between normal bronchial epithelial cells (HBEC) and lung cancer cells 
by suppression subtractive hybridisation (SSH) (Petersen et al. 2000, 
Diﬁlippantonio et al. 2003, An et al. 2003). Our data suggest that BrdU 
induced cell differentiation is linked to the development of a less ag-
gressive phenotype in SCLC (Chen et al. 2007a).
Inactivation of connexin26 (Cx26) in lung cancer is caused by pro-
moter hypermethylation.
Cx26 is one of the gap junction proteins. Intercellular communication 
via gap junction is a mechanism for tumor suppression. We analyzed 
the expression of Cx26 and found that it was downregulated in lung 
cancer cell lines and primary lung tumors by promoter hypermethyl-
ation (Chen et al. 2004).
Insulin-like growth factor binding protein-related protein 1 
(IGFBP-rP1) has tumor suppressive activity in lung cancer.
IGFBP-rP1 has decreased expression in various tumors. We ﬁrst ana-
lyzed the expression of IGFBP-rP1 in lung cancer and found that it was 
downregulated. Forced expression of IGFBP-rP1 by stable transfection 
dramatically reduced tumorigenic potential both in vitro and in vivo, and 
increased the number of apoptotic cells. Demethylation test with 5-aza-
2’-deoxycytidine and sequencing of PCR products of sodium bisulﬁte-
treated genomic DNA provided direct evidence that downregulation of 
IGFBP-rP1 can be explained by DNA methylation. Our data suggest 
that IGFBP-rP1 is a tumor suppressor in lung caner acting possibly via 
DNA methylation and induction of apoptosis (Chen et al. 2007b). 
Pituitary homeobox 1 (PITX1) in lung carcinogenesis.
The PITX1 gene has essential roles in human development and differ-
entiation. In our study, we analyzed the expression of PITX1 in cancer 
cell lines and primary lung tumors at both mRNA and protein levels 
and found that PITX1 was downregulated in lung cancer by Northern 
blot and Western blot analysis. In primary lung tumors analyzed by 
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tissue microarray, the lower expression of PITX1 was found to be 
signiﬁcantly linked to higher tumor stages. Additionally, increased 
PITX1 expression was found in a NSCLC cell line H2228 and a SCLC 
cell line H526 after they were exposed to the differentiation modifying 
agent BrdU indicating the potential role of PITX1 in lung cancer dif-
ferentiation and carcinogenesis (Chen et al. 2007c).
LAGY/HOP, a novel tumor suppressor in lung cancer.
Previously, we ﬁrst isolated the full-length sequence of LAGY/HOP 
and observed that this gene was downregulated in a panel of lung can-
cer cell lines as well as in a majority of primary lung tumors (Chen et 
al. 2003). Recently, we constructed an expression vector containing the 
full-length cDNA of LAGY/HOP and transfected it into the lung cancer 
cell line H2170. Stable transfection led to an increased expression of 
LAGY/HOP. LAGY/HOP positive transfectants remarkably reduced 
the growth rate and the ability of anchorage-independent growth in 
soft agar, and moreover suppressed the tumor formation in nude mice. 
Transient transfection of Nkx2.1 into H2170 resulted in the overexpres-
sion of LAGY/HOP, and correspondingly, siRNA silencing of Nkx2.1 
reduced the expression of LAGY/HOP in lung cancer cells. Further-
more, increased expression of LAGY/HOP was observed in the BrdU 
modiﬁed differentiation cell model. Our data suggest that LAGY/HOP 
is a potential tumor suppressor possibly involved in lung cancer differ-
entiation, and functions downstream of Nkx2.1 (Chen et al. 2007d).
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Genetic and proteomic proﬁling of lung cancer has given way to a 
number of molecularly targeted therapeutics. As new molecules are 
identiﬁed to be important in lung cancer, we will need to determine 
their role as prognosticators and ultimately as predictive markers. 
A prognostic marker helps determine the progression of lung cancer 
and ultimate outcome; whereas, a predictive marker represents how a 
patient may respond to a particular type of treatment. Studies of recep-
tor tyrosine kinases (RTKs), such as epidermal growth factor receptor 
(EGFR) and Met, have also lead to therapeutic target inhibition in solid 
tumors. In particular, overexpression of EGFR is a poor prognostica-
tor in a number of solid tumors, especially lung cancer. Using small 
molecule inhibitors (such as erlotinib) and antibody (such cetuximab) 
against EGFR, a number of predictive markers have been utilized. The 
predictive markers can include expression of EGFR, phosphorylated 
EGFR, and downstream targets such as Akt via immunohistochemistry 
(IHC). Predictive markers for EGFR therapies also include gene ampli-
ﬁcation (with FISH) and mutational analysis. In spite of a large number 
of studies on EGFR and EGFR inhibitors, there is no clear consensus 
on the use of predictive markers. Some important facts that are emerg-
ing: 1. Mutational status of EGFR is predictive of response; 2. FISH is 
predictive of survival; 3. K-ras mutation is a negative predictor; 4. Rash 
is prognostic but not necessarily predictive. Met is another RTK that 
is overexpressed in lung cancer, sometimes ampliﬁed, as well poten-
tially mutated. The mutations of Met rarely occur in the tyrosine kinase 
domain in lung cancer; however, a large number of mutations are in 
the semaphorin domain as well in the juxtamembrane (JM) domain. 
These mutations lead to gain of functions, and there appears to be a 
difference in mutations in various histologies as well in different ethnic 
backgrounds. We have identiﬁed that Met and its ligand, hepatocyte 
growth factor (HGF), are important prognosticators in lung cancer. 
There are several inhibitors agains Met/HGF that are already in clinical 
trials. It is to be determined with the various Met inhibitors if there are 
also predictive markers, and this will be discussed. Certainly, there are 
a large number of markers that are prognostic/predictive in lung cancer 
(such as the recently identiﬁed ERCC1 and RRM1; and a plethora of 
other gene/protein markers); however, rigorous prospective validation 
of biological and clinical markers of sensitivity needs to be performed.
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Lung cancer is the most serious cause of cancer mortality worldwide. 
The current clinical staging system can not accurately predict risk of 
patients. To develop an outcome prediction method for personalized 
therapy of lung cancer is the most important goal of cancer genomics.. 
To identify gene signature that can predict survival and metastasis in 
lung cancer patients, we examined the gene expressions in surgical 
specimens of 125 NSCLC patients using microarray and real-time RT-
PCR and correlated with survival of the patients. We used the risk score 
and decision-tree methods to develop a gene-expression predictive 
model to predict the clinical outcome of NSCLC. We have identiﬁed 
sixteen genes that correlated with patient survival. We then selected 
5 genes (DUSP6, MMD, STAT1, ERBB3 and LCK) and developed a 
risk predictive model based on RT-PCR and decision-tree approach. 
The 5-gene signature is an independent predictor of cancer recurrence 
and overall survival of NSCLC patients. We validated the model in an 
independent cohort of 60 NSCLC patients and also in an independent 
set of 86 western patients from published microarray data. This study 
can identify the patients with high risk gene signature in early stage. 
It may be a useful tool for risk prediction and designation of adjuvant 
treatment for high risk patients after validation in a prospective clini-
cal trial. To move a step forward, we identiﬁed a unique microRNA 
signature that can predict the survival and relapse of 112 NSCLC 
